Anti-CA9 monoclonal antibody, clone HU25323

Generally, the Luminescence properties of phosphors can be tuned by cations substitutions (Mg2+, Ca2+, Sr2+ and Ba2+); however, the underlying mechanism is not dear. The Luminescence properties are influenced by many factors, such as symmetry of the Ligand poLyhedron and the bond Length between the Luminescent centre and its Ligand. Therefore, in this research, the phosphor Ca9-x-y-zMgxSryBazCe(PO4)(7):Eu2+,Mn2+ was selected as the research object, and the reasons are investigated. Detailed data regarding the crystal space structure is acquired through the Rietveld refinement and used to systematically analyze the change of the two factors. It was found that the two factors are sometimes synergetic and sometimes antagonistic to the spectrum shift. The change of the Luminescence properties is the comprehensive result of the two factors. It was found that the influence produced by the change of symmetry of the poLyhedron is stronger than that by the change of bond Length between the Luminescence centre and its Ligand. When changing the doping concentration of Sr2+ and Ba2+, the chromaticity coordinates of (Ca,Sr,Ba)(8.78)Ce(PO4)(7):Eu2+,Mn2+ could change from cold white Light to warm white Light, and there is a Larger distribution range in the white Light region in the CIE 1931 chromaticity diagram. Cations substitutions tuning the Luminescence thermal stability are also observed. When partial Ca2+ are substituted by other cations, the Luminescence thermal stability of the Luminescent centre was improved to some degree. It is expected that these methods can be generalized to analyze the changes in optical and other properties that are sensitive to Local coordination environments for Luminescent materials.

Background: The immunosuppressive tumor microenvironment (TME) contributes to the tumor progression and treatment failure. Our previous study demonstrated alterations in the TME during bevacizumab (Bev) therapy in human glioblastoma (GB) specimens obtained from patients who underwent surgical resection. Continuous Bev administration downregulates the expression of programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1), suppresses the infiltration of tumor associated macrophages (TAMs) and regulatory T cells (Tregs), and increases cytotoxic T lymphocytes (CTLs) infiltration. However, one may argue that these immunosupportive effects might also be induced by radiation therapy (RT) or temozolomide (TMZ), and they cannot necessarily be attributed to Bev alone. Methods: In the present study, changes in the molecules relevant to the TME were analyzed by immunohistochemistry using paired pre- and post-treatment samples of malignant glioma specimens from 15 patients who received RT and TMZ therapy without Bev. Results: The expression levels of CD34, vascular endothelial growth factor (VEGF)-A, VEGF receptor 2 (VEGFR2), HIF-1 alpha, CA9, nestin, CD4, CD8, CD163, PD-1, and PD-L1 were not significantly changed after the treatment with RT and TMZ. However, VEGFR1 expression and the number of Foxp3-positive cells tended to be upregulated and increased after the treatment (P=0.058, P=0.082, respectively). Conclusions: This was the first study to show the alterations of TME following RT and TMZ therapy using paired pre- and post-treatment malignant glioma samples. Long-term treatment of RT and TMZ might worsen immunosuppressive TME in malignant gliomas.